• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

June 17, 2020

Study: No Link Between Ertugliflozin and Increased Risk of Cardiac Events

Author(s):

Sara Karlovitch Assistant Editor

Ertugliflozin is a relatively new addition to the SGLT2 inhibitor class of medication.

Ertugliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, does not impact the likelihood of stroke, heart attack, or cardiac related death in patients with type 2 diabetes (T2D), a new phase 3 study has found.

Ertugliflozin is a relatively new addition to the SGLT2 inhibitor class of medication, according to the investigators. Usually, ertugliflozin is prescribed along with a diet and exercise program meant to improve glycemic control in those with T2D, according to the study’s presentation at the American Diabetes Association’s (ADA) 80th Virtual Scientific Sessions.

The study—“Results of the eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)”—was composed of 8246 individuals aged 40 years and older. Each participant had T2D and a documented history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems. The participants were randomly divided into 3 groups. The first group, which was made up of 2747 participants, received 15 mg of ertugliflozin. The second group, made up of 2752 participants, received 5 mg. The third group, made up of the remaining 2747 participants, received a placebo.

Researchers found that those taking ertugliflozin had similar rates of cardiovascular death, heart attack, and stroke. Of the 5493 patients taking ertugliflozin, the primary outcome occurred in 653 individuals or 11.9%. The primary outcome occurred in 327 members (11.9%) of the placebo group, according to researchers. While ertugliflozin alone did not prove to decrease overall risk of cardiovascular death or hospitalization, the study results showed those taking ertugliflozin had a lower rate of heart failure and hospitalization compared to the placebo group.

“Our research supports the recent guideline updates indicating the use of this class of drugs for patients with diabetes who have prior atherosclerotic heart disease, heart failure, or chronic kidney disease. Patients with type 2 diabetes who have heart disease should discuss with their doctor whether SGLT2 inhibitors may be appropriate for their treatment,” said lead VERTIS-CV researcher Christopher Cannon, MD, professor of medicine at Harvard Medical School, Senior Physician in the Cardiovascular Division at Brigham and Women’s Hospital, and Education Director at the Cardiovascular Innovation Group, in a press release.

The safety of ertugliflozin is consistent with other SGLT2 inhibitors, according to the press release. The rates of amputations were 0.6 and 0.5 per 100 patient years.

REFERENCE

International Study of More Than 8,000 People Showed Ertugliflozin Does Not Increase Risk of Cardiac Events [news release]; Chicago IL June 16, 2020; American Diabetes Association; Accessed June 17, 2020

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Patient receiving diabetes consultation -- Image credit: Syda Productions | stock.adobe.com
Related Content
Advertisement
Drawn to Understand: How Culturally Tailored Education Empowers Patients With Type 1 Diabetes
July 1st 2025

Drawn to Understand: How Culturally Tailored Education Empowers Patients With Type 1 Diabetes

Dina Alsalih, PharmD, PhD, MBA
Pharmacy Focus: Limited Series: Celebrity Endorsements in Ozempic
March 13th 2024

Pharmacy Focus: Limited Series: Celebrity Endorsements in Ozempic

Ashley Gallagher, Editor
Diabetes - Image credit: Sherry Young | stock.adobe.com
June 27th 2025

Condition Watch: Diabetes

Kennedy Ferruggia, Assistant Editor Aislinn Antrim, Managing Editor Huiqiao (Melinda) Fan, BSc
Pharmacy Focus: Turning the Tide On Obesity - Episode 2
September 13th 2023

Pharmacy Focus: Turning the Tide On Obesity - Episode 2

Laboratory scientist looking at test tubes with blood and analysis -- Image Credit: Анна Ковальчук | stock.adobe.com
June 26th 2025

Understanding the Link Between SGLT2 Inhibitors, Red Blood Cell Counts, and Blood Clots in Adults With Type 2 Diabetes

Danielle Valletti, Assistant Editor
Hand holding Ozempic Insulin injection pen for diabetics - Image credit: Natalia | stock.adobe.com
June 24th 2025

ADA 2025: Combination of Bimagrumab and Semaglutide Shows Enhanced Fat Loss and Muscle Preservation

Kennedy Ferruggia, Assistant Editor
Related Content
Advertisement
Drawn to Understand: How Culturally Tailored Education Empowers Patients With Type 1 Diabetes
July 1st 2025

Drawn to Understand: How Culturally Tailored Education Empowers Patients With Type 1 Diabetes

Dina Alsalih, PharmD, PhD, MBA
Pharmacy Focus: Limited Series: Celebrity Endorsements in Ozempic
March 13th 2024

Pharmacy Focus: Limited Series: Celebrity Endorsements in Ozempic

Ashley Gallagher, Editor
Diabetes - Image credit: Sherry Young | stock.adobe.com
June 27th 2025

Condition Watch: Diabetes

Kennedy Ferruggia, Assistant Editor Aislinn Antrim, Managing Editor Huiqiao (Melinda) Fan, BSc
Pharmacy Focus: Turning the Tide On Obesity - Episode 2
September 13th 2023

Pharmacy Focus: Turning the Tide On Obesity - Episode 2

Laboratory scientist looking at test tubes with blood and analysis -- Image Credit: Анна Ковальчук | stock.adobe.com
June 26th 2025

Understanding the Link Between SGLT2 Inhibitors, Red Blood Cell Counts, and Blood Clots in Adults With Type 2 Diabetes

Danielle Valletti, Assistant Editor
Hand holding Ozempic Insulin injection pen for diabetics - Image credit: Natalia | stock.adobe.com
June 24th 2025

ADA 2025: Combination of Bimagrumab and Semaglutide Shows Enhanced Fat Loss and Muscle Preservation

Kennedy Ferruggia, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.